The present invention is related to a fixed dose combination tablet formulation comprising the glycosidase inhibitor acarbose (O-4,6-Didesoxy-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino}-α-D-glucopyranosyl-(1,4)-O-α-D-glucopyranosyl-(1,4)-D-glucopyranose) and the glycerin-3-phosphate-Dehydrogenase inhibitor metformin (1,1-Dimethylbiguanid), particularly the hydrochloride salt of metformin. Also provided are processes for producing a fixed dose combination tablet formulation.本發明係關於包括葡萄糖酶抑制劑阿卡波糖(O-4,6-雙去氧-4-{[(1S,4R,5S,6S)-4,5,6-三羥基-3-(羥甲基)-2-環己烯-1-基]胺基}-α-D-吡喃葡萄糖基-(1,4)-O-α-D-吡喃葡萄糖基-(1,4)-D-吡喃葡萄糖)和甘油-3-磷酸脫氫酶抑制劑甲福明(metformin)(1,1-二甲基雙胍)，特別是甲福明之鹽酸鹽的固定劑量組合錠劑配製物。亦提供製造固定劑量組合錠劑配製物之方法。
